Venetoclax plus decitabine, cytarabine, aclarubicin, and G‐ CSF in adults with newly diagnosed acute myeloid leukemia: A multicenter, retrospective study

作者：Ying Zhang, Kun Yang, Yong Guo, Jin Rao, Feng Wang, Yunfan Yang, Zhongqing Zou, Kai Shen, Chunyan Liang, Hongwei Wu, Chenlu Yang, Wenjiao Tang, Yantao Ling, Yiwen Du, Jirui Tang, Mei Wang, Duanzhong Zhang, Xiaoling Yu, Qi Chen, Yanqiu Xiong, Xu He, Yuchen Zhan, Hongbin Ma, Yuping Gong · 发表于：International Journal of Cancer · 年份：2025 · DOI：10.1002/ijc.70239 · 被引用次数：1 · 研究领域：Acute Myeloid Leukemia Research、Neutropenia and Cancer Infections、Hematopoietic Stem Cell Transplantation

This multicenter, retrospective study evaluated the efficacy and safety of the venetoclax plus decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (VD-CAG) regimen in newly diagnosed acute myeloid leukemia (ND-AML) patients aged 18-60. The analysis included, but was not limited to, the composite complete response (CRc) rate, measurable residual disease (MRD) negativity rate, overall survival (OS), event-free survival (EFS), and safety. A total of 107 adult patients with AML were included in the study, conducted between March 1, 2022, and December 31, 2024. The median age was 49 years (range: 18-60 years), with a male-to-female ratio of 44:63. The CRc rate after one cycle of the VD-CAG regimen was 86.9% (95% CI 79-92.7; 93 of 107 patients) in the entire cohort. 73 (79%) of 93 patients who reached CRc had undetectable MRD. Grade 3 or worse adverse events included neutropenia in 107 (100%) of 107 patients, thrombocytopenia in 107 (100%), anemia in 107 (100%), febrile neutropenia in 57 (53%), pneumonia in 10 (9.3%), sepsis in five (4.7%), and tumor lysis syndrome in three (2.8%). No treatment-related deaths occurred. With a median follow-up of 8.8 months (range: 1-33.5 months), the median EFS and OS are not reached. The estimated 12-month OS was 90% (95% CI 90-95) and 12-month EFS was 79% (95% CI 69-87). The VD-CAG regimen represents an effective induction therapy for young ND-AML. It leads to high rates of CRc and MRD-negative remissions, along with en...